OVID: Ovid Therapeutics Inc Growth-Adjusted Market Cap to Net Income
The scientific staff of Ovid Therapeutics Inc. (OVID), attracted by generous R&D budgets, shapes the P/E to growth ratio dynamics, where the 0.00 indicator determines the parameter status. Business value is dictated by trial results rather than macroeconomics or inflation. The focus on innovative epilepsy therapy in an active development phase confirms the company's high value potential.
Analytical breakdowns for Ovid Therapeutics Inc (OVID)
- current price and projected stock value:
- market capitalization information:
- company book value details:
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Ovid Therapeutics Inc.|OVID - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Ovid Therapeutics|OVID - Company Aggregate Debts|Debts to Book Value Ovid Therapeutics|OVID - Company Long-Term Debt|Company Short-Term Loans and Borrowings Ovid Therapeutics|Quick Ratio ovidrx.com
- net income and valuation multiples indicators:
OVID - Company Net Income|Forward Earnings Ovid Therapeutics Inc.|OVID - P/E Multiple|Projected Price to Earnings Ratio Ovid Rx|OVID - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Ovid Therapeutics Inc.|OVID - Operating profit before deduction of amortization|Earnings per share for the last four quarters Ovid Therapeutics|OVID - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months ovidrx.com|OVID - Earnings growth in current year|Expected earnings per share growth for next year Ovid Therapeutics Inc.
- sales revenue and business income indicators:
General company analysis:OVID - Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (OVID) is optimizing clinical trials through the automation of biodata collection, thereby reducing operating expenses. The efficiency of such innovations is reflected in the ratio of the P/E multiple to projected earnings growth rates. This metric determines the cost of a unit of growth, identifying assets with undervalued development potential. Analysis via the undervalued growth company search indicator on GURU.Markets allows for the identification of entry points when the value falls below one.
Competitors of Ovid Therapeutics Inc.
Growth-Adjusted Market Cap to Net Income Biogen Idec|Neurocrine Corp - Price/Earnings to Growth Multiple|regencellbioscience.com (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Growth-Adjusted P/E Ratio|Xenon Pharmaceuticals (XENE) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus|Price to Earnings Adjusted for Growth Rate catalystpharma.com CPRX|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics Inc.)|HRMY - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Biohaven Ltd. BHVN|AMLX (Amylyx) - Market Cap to Earnings and Growth Ratio|Trevi Therapeutics Inc - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Precision Medicines)|AVXL: PEG Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio prothena.com|Price/Earnings to Growth Multiple Alector (ALEC)|Price/Earnings to Growth Multiple ANNX (annexonbio.com)|OMER - Price to Earnings Adjusted for Growth Rate|PEG Multiple NGNE (Neurogene Inc)|PEG Multiple AC Immune S.A. ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX (Scilex Holding Company) - Price/Earnings to Growth Multiple|TVGN (Tevogen Bio Holdings) - Price/Earnings to Growth Ratio|ACOG (Alpha Cognition Corp) - PEG Multiple|Cognition Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|PEG Multiple IKT|SAVA (Cassava) - Growth-Adjusted Payback Ratio|Assertio Holdings, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio COYA|VistaGen Therapeutics, Inc. - PEG Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Multiple|CRVO (CervoMed, Inc.) - Price/Earnings to Growth Multiple|Price/Earnings to Growth Multiple Alterity Therapeutics Ltd|Price/Earnings to Growth Ratio Clene Inc.|PepGen Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple JUNS (Jupiter Neurosciences Inc)|Price/Earnings to Growth Ratio RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Grace Tx (GRCE)|fireflyneuro.com - PEG Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio RVPH (Reviva Pharmaceuticals Holdings, Inc.)|MTVA (MetaVia) - PEG Multiple|NRXS: Growth-Adjusted Payback Ratio|PEG Multiple HSDT|PEG Multiple Passage Bio Inc. (PASG)|Price/Earnings to Growth Ratio bionomics.com.au NEUP|PEG Multiple Minerva Neurosciences Inc NERV|ATHA: Price/Earnings to Growth Multiple|ADXN (Addex Therapeutics, Ltd.) - Growth-Adjusted P/E Ratio|Alzamend Neuro Inc. (ALZN) - Price/Earnings to Growth Ratio|Cyclerion - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio protagenic.com|Pasithea Therapeutics - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple
